Human Papillomavirus
Conditions
Interventions
Participants will receive three injections of either the bivalent (Cervarix®) or nonavalent
(Gardasil9®) HPV vaccine. In Part I twelve venous blood samples will be drawn and in Part II
eight venous bl
Sponsors
Dutch Ministry of Health, welfare and Sports
Eligibility
Inclusion criteria
Inclusion criteria: ? Seronegative for hr-HPV vaccine types(16,18,31,33,45,52,58) ? Female ? Normal general health ? Pre-menopausal ? Willing to receive HPV vaccination ? Provision of written informed consent ? Willing to adhere to the protocol and be available during the study period
Exclusion criteria
Exclusion criteria: present evidence of serious disease(s) within the last 3 months before inclusion requiring immunosuppressive or immune modulating medical treatment, such as systemic corticosteroids, that might interfere with the results of the study; ? chronic infection ? known or suspected immune deficiency; ? history of any neurologic disorder, including epilepsy; ? previous administration of serum products (including immunoglobulins) within 6 months before vaccination and blood sampling ? known or suspected allergy to any of the vaccine components (by medical history) ? previous vaccination with any HPV vaccine ? pregnancy ? participating in another vaccination/ medicine study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To obtain insight into signature of immune responses triggered by a bivalent- or nonavalent HPV vaccination. | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the most informative time-points to study diff | — |
Contacts
Public ContactHella Pasmans
RIVM
Outcome results
None listed